Search Clinical Trials

Clinical Trials Category

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

46 results for "Cancer" and "Gastrointestinal Cancers"

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

The purpose of this study is to test the anti-cancer activity of NUC-1031 when given in
combination with Cisplatin, and to compare it with the standard treatment of Gemcitabine in
combination with Cisplatin in people with biliary tract cancer.
Protocol No
NUCANA-NUTIDE-121
Sub Category
Gastrointestinal Cancers

Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer (SOLARIS). This study is being done to answer the following question: Can we lower the chance of your colorectal cancer growing or spreading by adding a new drug to the usual combination of drugs?
Protocol No
ALLIANCE-A021703-SOLARIS
Sub Category
Gastrointestinal Cancers

A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

The purpose of this study is to compare the effects, good or bad, of Atezolizumab plus
Bevacizumab versus observation (not receiving any treatment) on patients with completely
resected or ablated HCC who are at high risk for disease recurrence.
Protocol No
GENENTECH-WO41535-IMBRAVE050
Sub Category
Gastrointestinal Cancers

Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events

This study is being done to answer the following questions: Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively? To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...
Protocol No
ALLIANCE-A151804
Sub Category
Gastrointestinal Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Sub Category
Gynecologic Cancers
Prostate and Urologic Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Head and Neck Cancers
Gastrointestinal Cancers

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer.

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Protocol No
SWOG-S1602
Sub Category
Prostate and Urologic Cancers

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
Protocol No
PFIZER-B7461009
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
Breast Cancers

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Phase 3 Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in mCRPC
Protocol No
MERCK-MK-7339-010
Sub Category
Prostate and Urologic Cancers
Share This: